Agalliu, llirOrtega, Roberto A.San Luciano, MartaMirelman, AnatPont-Sunyer, ClaustreBrockmann, KathrinVilas, DoloresTolosa, EduardoBerg, DanielaWarø, BjørgGlickman, AmandaRaymond, DeborahInzelberg, RivkaRuiz-Martinez, JavierMondragon, ElisabetFriedman, EitanHassin-Baer, SharonAlcalay, Roy N.Mejia-Santana, HelenAasly, JanForoud, TatianaMarder, KarenGiladi, NirBressman, SusanSaunders-Pullman, Rachel2019-12-192019-12-192019-09Agalliu, I., Ortega, R. A., Luciano, M. S., Mirelman, A., Pont-Sunyer, C., Brockmann, K., … Saunders-Pullman, R. (2019). Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls. Movement disorders : official journal of the Movement Disorder Society, 34(9), 1392–1398. doi:10.1002/mds.27807https://hdl.handle.net/1805/21512BACKGROUND: Increased cancer risk has been reported in Parkinson's disease (PD) patients carrying the leucine rich repeat kinase 2 (LRRK2) G2019S mutation (LRRK2-PD) in comparison with idiopathic PD (IPD). It is unclear whether the elevated risk would be maintained when compared with unaffected controls. METHODS: Cancer outcomes were compared among 257 LRRK2-PD patients, 712 IPD patients, and 218 controls recruited from 7 LRRK2 consortium centers using mixed-effects logistic regression. Data were then pooled with a previous study to examine cancer risk between 401 LRRK2-PD and 1946 IPD patients. RESULTS: Although cancer prevalence was similar among LRRK2-PD patients (32.3%), IPD patients (27.5%), and controls (27.5%; P = 0.33), LRRK2-PD had increased risks of leukemia (odds ratio [OR] = 4.55; 95% confidence interval [CI], 1.46-10.61) and skin cancer (OR = 1.61; 95% CI, 1.09-2.37). In the pooled analysis, LRRK2-PD patients had also elevated risks of leukemia (OR = 9.84; 95% CI, 2.15-44.94) and colon cancer (OR = 2.34; 95% CI, 1.15-4.74) when compared with IPD patients. CONCLUSIONS: The increased risks of leukemia as well as skin and colon cancers among LRRK2-PD patients suggest that LRRK2 mutations heighten risks of certain cancers. © 2019 International Parkinson and Movement Disorder Society.en-USPublisher PolicyLRRK2 geneG2019S mutationParkinson’s diseaseLeukemiaColon cancerPooled analysisArticle